DFTX - Mind Medicine (MindMed) Inc.

17.55
-0.210   -1.197%

Share volume: 1,984,987
Last Updated: 03-05-2026
Pharmaceutical Products/Medicinal Chemicals: 2.23%

PREVIOUS CLOSE
CHG
CHG%
$17.76
-0.21
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 50%
Dept financing 37%
Liquidity 45%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.38%
1 Month
9.29%
3 Months
43.81%
6 Months
92.62%
1 Year
178.37%
2 Year
198.99%
Key data
Stock price
$17.55
P/E Ratio 
0.00
DAY RANGE
$17.04 - $18.07
EPS 
-$2.06
52 WEEK RANGE
$4.70 - $18.70
52 WEEK CHANGE
$168.68
MARKET CAP 
1.319 B
YIELD 
N/A
SHARES OUTSTANDING 
99.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,696,143
AVERAGE 30 VOLUME 
$1,518,126
Company detail
CEO: Robert Barrow
Region: US
Website: mindmed.co
Employees: 40
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Recent news